Biologic targeting in the treatment of inflammatory bowel diseases.

A trend toward significance was observed in the response at week 44 (eight weeks after the last infusion) in the infliximab-treated patients, compared with those receiving placebo.

also in 3,729 other papers

This maintenance study demonstrated a highly significant maintenance benefit, with the difference between the treatment groups at six months exceeding 30%. 152 Recently, the ability to taper or discontinue oral corticosteroids in patients treated with natalizumab, was evaluated in a randomized, double-blind, placebo-controlled, multicentric study (ENACT-2). 153 The results of this study demonstrated that natalizumab seems to be associated with steroid-sparing effects in patients with CD as evidenced by the ability of the drug to sustain clinical response and/or remission over time following the withdrawal of concomitant corticosteroids.

also in 132,142 other papers